Do u really think HHS bends over for anyone? Along the same line, The Gates Foundation is giving Novavax $80 million to ensure that when the company's RSV vaccine is approved, underdeveloped countries will get it at the same time pregnant women, infants and older kids get it in the U.S. after the vaccine is approved. Neither organization bent over backwards for anyone. They both saw a desperate need elsewhere and want to level the playing field for all.
OraSure Technologies, Inc. announced today that it has made significant progress regarding the commercialization of its OraQuick® Ebola Rapid Antigen Test.
The Company announced that the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised an option to provide $7.2 million in additional funding for the Company's OraQuick® Ebola Rapid Antigen Test. This funding will be used primarily for clinical and regulatory activities required to request U.S. Food and Drug Administration (FDA) 510(k) clearance for this product. This option is part of the $10.4 million funding contract (base plus options) between OraSure and BARDA that was previously announced in June 2015.
The Company also announced today that HHS' Centers for Disease Control and Prevention (CDC) will purchase approximately $1.5 million of the Company's OraQuick® Ebola Rapid Antigen Test. The CDC purchase is expected to be fulfilled by the end of 2015. CDC is purchasing the OraQuick® Ebola Rapid Antigen Tests for field testing in West Africa. This is the second such purchase of this product for field testing made by CDC.
And if the test would work to tell if a guy is hot for a girl, a guy is hot for a guy and a girl is hot for a girl, that would cover all the bases. Orasure would not even need a marketing dept. Word of mouth would do it.